Key Considerations in Biosimilars Development

被引：0
|
作者：
Donninger, Raymond
Bower, Joe
Kaiser, Raymond
Estdale, Sian
Carlsen, John
机构：
来源：
BIOPHARM INTERNATIONAL | 2012年 / 25卷 / 10期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：37 / 39
页数：3
相关论文
共 50 条
  • [31] New and Generic Anticoagulants and Biosimilars: Safety Considerations
    Kalodiki, Evi
    Fareed, Jawed
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2011, 17 (02) : 136 - 139
  • [32] Methodological considerations for clinical equivalence of bevacizumab biosimilars
    Heinzmann, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] Biosimilars for the management of rheumatoid arthritis: economic considerations
    Gulacsi, Laszlo
    Brodszky, Valentin
    Baji, Petra
    Kim, HoUng
    Kim, Su Yeon
    Cho, Yu Young
    Pentek, Marta
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 : S43 - S52
  • [34] Biosimilars: considerations in light of the Italian legal framework
    Raffaelli, Enrico Adriano
    Massimino, Fausto
    GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2019, 8 (01): : 5 - 23
  • [35] Key considerations in formulation development for gene therapy products
    Mohammad, Rafi
    DRUG DISCOVERY TODAY, 2022, 27 (01) : 292 - 303
  • [36] Key considerations in the analysis of the development of social anthropology in Spain
    Óscar Fernández-Álvarez
    Miguel González-González
    Sara Ouali-Fernández
    International Journal of Anthropology and Ethnology, 7 (1)
  • [37] KEY DRIVERS FOR MARKET PENETRATION OF BIOSIMILARS IN EUROPE
    Remuzat, C.
    Dorey, J.
    Cristeau, O.
    Ionescu, D.
    Radiere, G.
    Mendoza, C.
    Toumi, M.
    VALUE IN HEALTH, 2016, 19 (07) : A497 - A497
  • [38] Monoclonal Antibodies Key to Unlocking the Biosimilars Market
    Challener, Cynthia A.
    BIOPHARM INTERNATIONAL, 2014, 27 (04) : 20 - 23
  • [39] Biosimilars in Developed Economies: Overview, Status, and Regulatory Considerations
    Rathore, Anurag S.
    Bhargava, Ankita
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2020, 110
  • [40] Current regulatory and scientific considerations for approving biosimilars in Iran
    Hadavand, Naser
    Valadkhani, Mahboubeh
    Zarbakhsh, Aida
    BIOLOGICALS, 2011, 39 (05) : 325 - 327
12345